Back to News
Market Impact: 0.3
Alpha Tau Gains FDA Approval For REGAIN Trial Expansion In Recurrent Glioblastoma; Shares Rise
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
The FDA approved an Investigational Device Exemption supplement for Alpha Tau Medical, allowing expansion of its REGAIN study in recurrent glioblastoma. The report provides no enrollment figures, trial outcomes, or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
DRTS0.65
More News
- ’Panic’ selling hits Indonesian markets on MSCI expulsion threat
- Egyptian parliament delays vote on military support for Saudi Arabia
- DeepSeek deep-sixed at all US federal civilian agencies
- We're buying more of a beaten-up stock before another overhang is lifted
- Crushed tech stocks bounce — plus, new doctor survey keeps us positive on Lilly
- Capital One, General Motors are among the stocks reporting this week with momentum. Here are the others